Physician profile
Grace Chan
NPI 1538664438
$5,948.52
in general payments reported to CMS, 2019-2025
12 companies · $1,014 in 2025
The $1,014 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $404 · 2023: $1,717 · 2024: $2,813 · 2025: $1,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,813 · Travel and Lodging: $555 · Education: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,813.27 |
| Travel and Lodging | $555.29 |
| Education | $175.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,967.23 | 2023-2025 | Rinvoq, Botox |
| Ucb, INC. | $893.70 | 2022-2025 | Bimzelx |
| Genzyme Corporation | $694.41 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $524.32 | 2024-2025 | Spevigo |
| Janssen Biotech, INC. | $515.68 | 2023-2025 | Tremfya, Stelara |
| Dermavant Sciences, INC. | $397.84 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $226.76 | 2023-2024 | Dupixent |
| Galderma Laboratories, L.P. | $218.72 | 2022-2024 | |
| Krystal Biotech INC | $178.34 | 2024 | Vyjuvek |
| E.R. Squibb & Sons, L.L.C. | $120.12 | 2022 | |
| Organon LLC | $115.70 | 2025 | Vtama |
| Janssen Scientific Affairs, LLC | $95.70 | 2024 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.